Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Post by moneywagonon Oct 17, 2022 11:05am
173 Views
Post# 35028918

BIOV WE KISSED@14~BELOW DEBT ISSUANCE @15~SADDLE UP PEEPS

BIOV WE KISSED@14~BELOW DEBT ISSUANCE @15~SADDLE UP PEEPSGoood morning BIOV....nice pullback, saddle up people, nice place to add....if you are here screen watching hopefully its to catch the bottom. I DO NOT suspect many shares for sale down here. Brokers, investors paytiently waiting. 
The pullback is certainly welcoming for those entering or adding and it was no surprise to the experienced trader that the... sp would downtrend to sp contract debt relief.

It is perfectly NORMAL. Sp reacts UP or down to all pp/contract  blah blah to the increments...and again totally normal the sp has licked just under @15.

I repeat, the prior run, SP slapped @255....that was just a practise run!! 
Volume is sparce, global markets.....environmental fear.
Shareprice will recover back into the @20's, but it will be a nice n slow uptick cuz of no market volume...tic tock
Just be ready!
No shares up on the ASK....is a sure reciper.....the Bulls gotta move up , simple dimple.

Currently the shareprice is looking for support @15

("BioVaxys" or the "Company") announces that, further to its news release dated October 6, 2022, it has settled an aggregate of $300,000 in debt through the issuance of common shares issued at a deemed price of $0.15 per common share.
<< Previous
Bullboard Posts
Next >>